INTRODUCTION: The long-term results of the Spanish Study Protocol SEOP-SO-95 for treatment of localised osteosarcoma of the extremities in children were evaluated. PATIENTS AND METHODS: One hundred consecutive patients under 18 years of age from 22 institutions were enrolled from January 1995 to December 2000. Immunohistochemical expression of p53, HER/erbB-2 and P-glycoprotein were retrospectively studied in 27 patients. Treatment consisted of: preoperative chemotherapy with doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue and ifosfamide for 14 weeks; surgery of primary tumour in week 16; postoperative chemotherapy with the above-mentioned drugs for 25 weeks. RESULTS: With a median follow-up of 124 months (range 84-158 months), 69 patients (69%) were continuously event-free survivors; the 10-year probability of event-free survival (EFS) was 62%. Conservative surgery was performed in 85% of patients. Twenty-six patients had local recurrence or distant relapse. The median time to recurrence/ relapse was 27 months (range 17-93 months). The local recurrence rate was 7% (7 of the 100 patients); 4 had wide surgical margins, 2 marginal and 1 intralesional. Four patients died as a result of chemotherapy-related toxicity and 1 developed a second neoplasia (acute myeloid leukaemia). p53 expression and HER2/erbB-2 expression showed no effect on survival or EFS. CONCLUSIONS: This therapeutic protocol achieved good oncologic and orthopaedic results. We observed a significant treatment-related toxicity.
INTRODUCTION: The long-term results of the Spanish Study Protocol SEOP-SO-95 for treatment of localised osteosarcoma of the extremities in children were evaluated. PATIENTS AND METHODS: One hundred consecutive patients under 18 years of age from 22 institutions were enrolled from January 1995 to December 2000. Immunohistochemical expression of p53, HER/erbB-2 and P-glycoprotein were retrospectively studied in 27 patients. Treatment consisted of: preoperative chemotherapy with doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue and ifosfamide for 14 weeks; surgery of primary tumour in week 16; postoperative chemotherapy with the above-mentioned drugs for 25 weeks. RESULTS: With a median follow-up of 124 months (range 84-158 months), 69 patients (69%) were continuously event-free survivors; the 10-year probability of event-free survival (EFS) was 62%. Conservative surgery was performed in 85% of patients. Twenty-six patients had local recurrence or distant relapse. The median time to recurrence/ relapse was 27 months (range 17-93 months). The local recurrence rate was 7% (7 of the 100 patients); 4 had wide surgical margins, 2 marginal and 1 intralesional. Four patients died as a result of chemotherapy-related toxicity and 1 developed a second neoplasia (acute myeloid leukaemia). p53 expression and HER2/erbB-2 expression showed no effect on survival or EFS. CONCLUSIONS: This therapeutic protocol achieved good oncologic and orthopaedic results. We observed a significant treatment-related toxicity.
Authors: N J Lindner; O Ramm; A Hillmann; R Roedl; G Gosheger; C Brinkschmidt; H Juergens; W Winkelmann Journal: Clin Orthop Relat Res Date: 1999-01 Impact factor: 4.176
Authors: W H Meyer; C B Pratt; C A Poquette; B N Rao; D M Parham; N M Marina; A S Pappo; H H Mahmoud; J J Jenkins; J Harper; M Neel; B D Fletcher Journal: J Clin Oncol Date: 2001-01-01 Impact factor: 44.544
Authors: Jun Ah Lee; Min Suk Kim; Dong Ho Kim; Jung Sub Lim; Ji Young Yoo; Jae Soo Koh; Soo-Yong Lee; Dae-Geun Jeon; Kyung Duk Park Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167
Authors: Allen M Goorin; Douglas J Schwartzentruber; Meenakshi Devidas; Mark C Gebhardt; Alberto G Ayala; Michael B Harris; Lee J Helman; Holcombe E Grier; Michael P Link Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: N Fuchs; S S Bielack; D Epler; P Bieling; G Delling; D Körholz; N Graf; U Heise; H Jürgens; R Kotz; M Salzer-Kuntschik; P Weinel; M Werner; K Winkler Journal: Ann Oncol Date: 1998-08 Impact factor: 32.976
Authors: M Onda; S Matsuda; S Higaki; T Iijima; J Fukushima; A Yokokura; T Kojima; H Horiuchi; T Kurokawa; T Yamamoto Journal: Cancer Date: 1996-01-01 Impact factor: 6.860
Authors: Cindy L Schwartz; Leonard H Wexler; Mark D Krailo; Lisa A Teot; Meenakshi Devidas; Laurel J Steinherz; Allen M Goorin; Mark C Gebhardt; John H Healey; Judith K Sato; Paul A Meyers; Holcombe E Grier; Mark L Bernstein; Steven E Lipshultz Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: Robert Grimer; Nick Athanasou; Craig Gerrand; Ian Judson; Ian Lewis; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan Journal: Sarcoma Date: 2010-12-29
Authors: Craig Gerrand; Nick Athanasou; Bernadette Brennan; Robert Grimer; Ian Judson; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan Journal: Clin Sarcoma Res Date: 2016-05-04